About Advaxis

Developing the Next Generation of Cancer Immunotherapy

Advaxis is a clinical stage biotechnology company.

Learn more

Clinical Pipeline

Clinical trials for the treatment of HPV-associated cancers

Axalimogene filolisbac (ADXS-HPV), Advaxis’ lead drug candidate, is in clinical trials for HPV-associated cancers. Of note, clinical trials for axalimogene filolisbac are currently placed on clinical hold.